{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-281199","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.835233+00:00","generated_at":"2026-06-22T02:07:16.150220+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IO Biotech reports Q3 net loss $15.7M; Phase 3 melanoma trial site activation accelerates; cash $151.2M","bullets":["Net loss $15.7M (vs $4.5M in Q3 2021); R&D expenses $10.0M (up from $4.1M) driven by Phase 3 trial costs.","Cash $151.2M as of Sep 30, 2022 (down from $211.5M at Dec 31, 2021); expected to fund operations into mid-2024.","Phase 3 trial site activation accelerated: 55 sites actively enrolling (up from 19 at end of July 2022).","Updated Phase 1/2 data: median OS 46.8 mo, median PFS 22.5 mo, complete response rate 50% in PD-1 naive patients.","Named Amy Sullivan as CFO in October 2022; new clinical collaboration with Merck for neoadjuvant/adjuvant trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-281199","json":"https://secwatch.observer/filing/0001193125-22-281199.json","markdown":"https://secwatch.observer/filing/0001193125-22-281199.md","text":"https://secwatch.observer/filing/0001193125-22-281199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522281199/0001193125-22-281199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522281199/d412247d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:07:16.150220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9050812f36399a9e1112b107b783e8b822878e59","claim":"IO Biotech, Inc. reported third quarter ended September 30, 2022 results: net income $15.7 million.","evidence_excerpt":"IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, announced today financial results for the quarter ending September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522281199/0001193125-22-281199-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"$15.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}